Congenital nephrotic syndrome responsive to captopril and indometacin.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 10490532.
- Also identified by PMC identifier 1718016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two children with congenital nephrotic syndrome are described (one with Finnish-type nephrosis, the other with diffuse mesangial sclerosis). Both children have had a prolonged and sustained clinical response with good physical health and normal growth patterns using captopril and indometacin as their sole treatment. No adverse effects have been noted. We recommend a trial of indometacin and captopril treatment in cases of congenital nephrotic syndrome.
Medical subject headings
- Angiotensin-Converting Enzyme Inhibitors
- Anti-Inflammatory Agents, Non-Steroidal
- Captopril
- Indomethacin
- Nephrotic Syndrome